Matthew Scholz

Matthew Scholz has a diverse work experience in various roles and industries. Matthew is currently the Chief Executive Officer of Oisin Biotechnologies, where they also serve as the Founder and on the Board of Directors. Oisin Biotechnologies focuses on developing therapeutics that target senescent cells for age-related pathologies and cancerous cells for solid tumors.

Additionally, Matthew Scholz is the Chief Executive Officer of OncoSenX, a company they joined in 2018.

In 2020, they co-founded Aegis Life, Inc. and holds the position of Chief Technical Officer.

In 2009, Matthew Scholz founded Immunusoft Corporation and served as the Founder, Chief Technology Officer, and later became the Chief Executive Officer. Under their leadership, Immunusoft grew into a gene therapy company that may soon go into clinical trials. The company has collaborated with major medical and research centers and received support from prominent investors.

Matthew also co-founded Sigma Genetics, Inc. and served on the Board of Directors.

Matthew Scholz was a Board Member at HiveBio Community Lab from 2013 to 2015.

Prior to their work in the biotechnology industry, they were the Chief Executive Officer of Point B Telematics from 2002 to 2008. The company specialized in GPS-based fleet logistics and they were responsible for founding the company, managing day-to-day operations, raising startup capital, and developing innovative technologies.

Matthew Scholz attended the University of Washington from 1998 to 2002, where they obtained a Bachelor of Science degree in Computer Science (CSS). In 2017, they also briefly attended Y Combinator for an unspecified program or course, but did not receive a degree or specialize in any specific field of study.